Dear Ms. Ramos:

Please refer to your Supplemental New Drug Application (sNDA) dated August 24, 2011, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Multaq (dronedarone hydrochloride) 400 mg Tablets.


This “Prior Approval” supplemental new drug application proposes revisions to the Medication Guide and proposed modifications to the approved REMS.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling, with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your
We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

**RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS**

The REMS for Multaq (dronedarone hydrochloride) was originally approved on July 1, 2009, and a REMS modification was approved on August 5, 2011. The REMS consists of a Medication Guide, a communication plan, and a timetable for submission of assessments of the REMS. Your proposed modifications to the REMS consist of:

- Revision of the REMS goals to:
  - Further specify the patient populations in which Multaq is contraindicated
  - Add a goal to inform healthcare professionals and patients about the increased risk of cardiovascular death, heart failure, and stroke in patients with permanent atrial fibrillation (AF);
- Revisions to the communication plan to include:
  - Dissemination of and posting on the Multaq REMS website of a Dear Healthcare Provider Letter warning about increased risk of death, stroke and heart failure in patients with permanent AF treated with Multaq;
  - Distribution of a prescriber checklist to assist healthcare providers in the identification of contraindications for Multaq use, as well as highlight the warnings and precautions for use;
- Minor clarifying revisions to the Medication Guide

The timetable for submission of assessments of the REMS will remain the same as that approved on July 1, 2009.

The REMS assessment plan has been revised to include a survey to evaluate the use of Multaq (dronedarone hydrochloride) in patients with permanent atrial fibrillation. Your revised REMS assessment plan should include, but is not limited to, the following:

1. Periodic surveys of healthcare professionals to monitor the effectiveness of the interventions in educating prescribers on the goals of the REMS and to monitor appropriate prescribing of Multaq (dronedarone hydrochloride)
2. Periodic surveys of patients to monitor the effectiveness of the interventions in educating patients on the safe and appropriate use of Multaq (dronedarone hydrochloride)
3. A report on periodic assessments of the distribution and dispensing of the Medication Guide in accordance with 21 CFR 208.24
4. A report on failures to adhere to distribution and dispensing requirements, and corrective actions taken to address noncompliance
5. Physician survey to evaluate the use of Multaq (dronedarone hydrochloride) in patients with permanent atrial fibrillation, including physician adherence to cardiac rhythm monitoring recommendations.
6. We remind you that assessments of an approved REMS must include, under section 505-1(g)(3)(B) and (C), information on the status of any postapproval study or clinical trial required under section 505(o) or otherwise undertaken to investigate a safety issue. With respect to any such postapproval study, you must include the status of such study, including whether any difficulties completing the study have been encountered. With respect to any such postapproval clinical trial, you must include the status of such clinical trial, including whether enrollment has begun, the number of participants enrolled, the expected completion date, whether any difficulties completing the clinical trial have been encountered, and registration information with respect to requirements under subsections (i) and (j) of section 402 of the Public Health Service Act. You can satisfy these requirements in your REMS assessments by referring to relevant information included in the most recent annual report required under section 506B and 21 CFR 314.81(b)(2)(vii) and including any material or significant updates to the status information since the annual report was prepared. Failure to comply with the REMS assessments provisions in section 505-1(g) could result in enforcement action.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:

**NDA 22425 REMS CORRESPONDENCE**
**(insert concise description of content in bold capital letters, e.g., UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT METHODOLOGY)**

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

Prominently identify the submission containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

**NDA 22425 REMS ASSESSMENT**

**NEW SUPPLEMENT FOR NDA 22425**
**PROPOSED REMS MODIFICATION**
**REMS ASSESSMENT**

**NEW SUPPLEMENT (NEW INDICATION FOR USE)**
**FOR NDA 22425**
**REMS ASSESSMENT**
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at http://www.fda.gov/opacom/morechoices/fdaforms/cder.html; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Russell Fortney, Regulatory Project Manager, at (301) 796-1068.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling
REMS
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
06/13/2012